Suppr超能文献

2,4,6-三甲氧基查尔酮衍生物的设计、合成、抗癌评估及计算机模拟研究

Design, Synthesis, anticancer evaluation and in silico studies of 2,4,6-trimethoxychalcone derivatives.

作者信息

Li Tong, Li Weiwei, Yang Xianjing, Chen Gong, Jin Xiaobao, Chen Weiqiang, Ye Lianbao

机构信息

School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Department of Laboratory Medicine, Guiyang Maternity&Child Health Hospital, Guiyang 550003, China.

出版信息

Saudi Pharm J. 2023 Jan;31(1):65-84. doi: 10.1016/j.jsps.2022.11.006. Epub 2022 Nov 16.

Abstract

Chalcone, a common chemical scaffold of many naturally occurring compounds, has been widely used as an effective template for drug discovery due to its broad biological activities. In this study, a series of chalcone derivatives were designed and synthesized based on the hybridization of 1-(2,4,6-trimethoxyphenyl)butan-1-one with chalcone. Interestingly, most of the target compounds exhibited inhibitory effect of tumor cells in vitro. Especially, (E)-3-(5-bromopyridin-2-yl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one () revealed over 10-fold potency than 5-fluorocrail against the Hela and MCF-7 cells with IC values of 3.204 and 3.849 μM respectively. Moreover, displayed low toxicity on normal cells. Further experiments indicated that effectively inhibited the proliferation and migration of tumor cells, and promoted their apoptosis. The calculation and prediction of ADME showed that the target compounds may have good pharmacokinetic properties and oral bioavailability. Reverse molecular docking suggested that the possible target of is CDK1. Taken together, these results suggested that appears to be a promising candidate that merits further attention in the development of anticancer drugs.

摘要

查尔酮是许多天然存在的化合物的常见化学骨架,由于其广泛的生物活性,已被广泛用作药物发现的有效模板。在本研究中,基于1-(2,4,6-三甲氧基苯基)丁-1-酮与查尔酮的杂化设计并合成了一系列查尔酮衍生物。有趣的是,大多数目标化合物在体外表现出对肿瘤细胞的抑制作用。特别是,(E)-3-(5-溴吡啶-2-基)-1-(2,4,6-三甲氧基苯基)丙-2-烯-1-酮()对Hela和MCF-7细胞的抑制活性比5-氟尿嘧啶高10倍以上,IC值分别为3.204和3.849 μM。此外,对正常细胞显示出低毒性。进一步的实验表明,有效地抑制了肿瘤细胞的增殖和迁移,并促进了它们的凋亡。ADME的计算和预测表明,目标化合物可能具有良好的药代动力学性质和口服生物利用度。反向分子对接表明,的可能靶点是CDK1。综上所述,这些结果表明,似乎是一种有前途的候选物,在抗癌药物开发中值得进一步关注。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a248/9845116/2294449d5b44/ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验